Home
overview

 

 

  

 

Asthma & COPD therapies provide one of the highest sources of revenue for the pharmaceutical industry. Having said this, the limited efficacy of many current products provides a strong incentive for research and development. Now in its 7th year, SMi’s Asthma & COPD conference will once again explore the latest advances and progress in the development of treatments for these respiratory disorders. The two-day conference will feature presentations on topics such as monoclonal antibodies, bronchodilators, selectin antagonists, kinases, device equivalence testing and measuring patient outcomes.

 "The COPD drug market in France, Germany, Italy, Japan, Spain, the UK and the USA was worth nearly $8.4 billion last year, according to a study by market analyst Decision Resources, but it forecasts that the ageing population means that the number of drug-treated patients will increase by nearly six million over the next decade."
 
Selina Mckee, PharmaTimes
November 23, 2010
 

The event will also feature a specialised workshop on Early Clinical Studies in COPD. This interactive half-day event will provide guidance on the use of biomarkers and ways of demonstrating proof of concept (PoC).  Attendees will benefit from being able to address issues specific to them and will have the opportunity to share experiences with industry associates.

 


 View the conference programme

 Register for the event

 Download the brochure

 


 

 

 Key topics at this year's conference:

 

  • Treating asthma with monoclonal antibody-based drugs
  • Anti-sense and DNAzym technologies
  • Models of exacerbations of asthma and COPD
  • Regulation of respiratory device equivalence testing
  • Long acting anticholinergics in asthma and COPD models
  • Evaluating outcomes in patients

Managers, Directors and Senior Scientists working at pharmaceutical or biotech organisations in the following areas;

  • Respiratory Science
  • Research & Development
  • Inflammation & Inhalation
  • Clinical & Regulatory Affairs
  • Drug Discovery
  • Respiratory Illness

 

  • Inhalation Drug Delivery
  • Project Management
  • Preclinical Development
  • Portfolio Management
  • Marketing
  • Drug Delivery

 

Previous delegates include;

3M Healthcare
Actimis
Activaero
AJH Partners
Almirall
Altair Therapeutics
Anacor Pharmaceuticals
AstraZeneca
Athor Management
Bedfont Scientific
Biomedical Systems
Biotie Therapies
Boehringer-Ingelheim
Cardinal Health Research Services
CareFusion
Celerion
Chiesi Farmaceutici
Deepbreeze
Domantis
Fibrex Medical
Fisher & Paykel Healthcare
Galapagos
Genentech
GlaxoSmithKline
Hydra Biosciences
Imperial College School of Medicine
Keele University-Centre For Health Planning And Management
Kings College London
Laboratorios Almirall
LCG Bioscience
MedImmune
Merck Sharp & Dohme
MicroDose Technologies
Napp Pharmaceuticals
National University Of Singapore
Novartis Pharmaceuticals
nSpire Health
Nycomed
Orion Clincial Services
Pacific Northwest National Laboratory
Pfizer
Roche Products
Sanofi Aventis Chinoin Rt.
Sanofi-Aventis
Sepracor
Sigmoid Pharma Limited
Synairgen
Syntaxin
Thomson Reuters
Topigen Pharmaceuticals
UCB
UCB-Celltech
University Hospital South Manchester
University Of Marburg
University Of Southampton School Of Medicine
Vectura
Vitalograph
Westberg Consulting
XSpray Microparticles
Zambon Group
Zambon
Zentiva

 

 

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Peter Barnes

Peter Barnes, Head of Respiratory Medicine, Imperial College

9:10 UNMET NEEDS IN ASTHMA AND COPD

Peter Barnes

Peter Barnes, Head of Respiratory Medicine, Imperial College

  • Current therapy for asthma is very effective but many patients are poorly controlled
  • For mild to moderate asthma more effective oral therapies and disease-modifying treatments needed
  • For severe asthma more effective add-on treatments needed
  • For COPD more effective anti-inflammatory treatments needed
  • Reversal of corticosteroid resistance as an alternative therapeutic strategy
  • Biomarkers to predict responder in asthma and COPD needed
  • 9:50 COPD and Asthma Regulatory Guidance

    John Warren

    John Warren, Medical Assessor, Formerly of the MHRA

  • European Notes for Guidance
  • COPD - new endpoints?
  • Asthma - identifying the place in the market
  • Hurdles for equivalence
  • 10:30 Morning Coffee

    11:00 NOVEL DRUGS AND TARGETS TO TREAT COPD

  • The need for new therapies and drug targets
  • VAP-1: A new drug target for COPD
  • BTT-1023, a therapeutic antibody against VAP-1 in clinical development for COPD
  • Ronomilast, a third generation PDE4 inhibitor designed to exploit the full potential of PDE4 inhibition in treating COPD
  • David Smith

    David Smith, VP Inflammatory Disease Area, Biotie Therapies

    11:40 TARGETING RESOLUTION OF INFLAMMATION IN CHRONIC INFLAMMATORY DISEASES OF THE LUNG

    Liz Hardaker

    Liz Hardaker, Investigator II, Novartis

  • Is chronic inflammation driven by compromised resolution?
  • Targeting resolution of inflammation in chronic inflammatory diseases
  • Developing in vivo models to investigate resolution of inflammation
  • Are the kinetics of resolution altered by tobacco smoke?
  • 12:20 Networking Lunch

    13:40 IS THERE A NEED FOR ANTI-INFLAMMATORIES BEYOND STEROIDS FOR COPD & ASTHMA?

    Mike Yeadon

    Mike Yeadon, Vice President, Head of Allergy and Respiratory Research, Pfizer

  • When steroids are not the (complete) answer
  • The ideal additional anti-inflammatory
  • How new targets that work will be identified
  • Kinase-based approaches
  • 14:20 COMPARATIVE EFFECTIVENESS OF INHALED CORTICOSTEROIDS (ICS) IN ASTHMA – CAN WE EVALUATE USING PRIMARY CARE DATABASES?

    Ewan Walters

    Ewan Walters, Medical Director, Teva UK Ltd

  • Performing studies using the MHRA General Practice Data Base (GPRD)
  • Evaluating outcomes in asthma patients taking individual ICS therapies
  • Particle size and device (inhaler) types that can influence outcomes in asthma patients
  • Making clinical management decisions to improve disease outcome measures
  • 15:00 Afternoon Tea

    15:40 TREATING ASTHMA WITH MONOCLONAL ANTIBODY-BASED DRUGS - PAST EXPERIENCE AND FUTURE PROSPECTS

    Matthew Catley

    Matthew Catley, Head of Respiratory Pharmacology, UCB

  • Clinical experience with monoclonal antibodies; anti-IgE, anti-TNF, anti-IL5
  • Patient stratification- The key to success
  • Future prospects for treating asthma with monoclonal antibodies
  • 16:20 DEVELOPMENT OF HERBAL MEDICINAL BIOACTIVE COMPOUNDS FOR RESPIRATORY DISEASES

    Fred Wong

    Fred Wong, Associate Professor, Department of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Singapore

  • Anti-malarial drug artesunate has anti-inflammatory effects in animal models of respiratory diseases
  • Artesunate prevents ovalbumin-induced allergic airway inflammation
  • Artesunate prevents cigarette smoke-induced acute lung injury
  • Artesunate suppressed oxidative stress in the airways
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Sebastian Johnston

    Sebastian Johnston, Professor of Respiratory Medicine, National Heart and Lung Institute, UK

    9:10 MODELS OF EXACERBATIONS OF ASTHMA AND COPD

    Sebastian Johnston

    Sebastian Johnston, Professor of Respiratory Medicine, National Heart and Lung Institute, UK

  • Rhinoviruses, allergens and bacteria are main precipitating agents
  • A human model of rhinovirus-induced asthma exacerbation permits mechanistic and therapeutic intervention study
  • A human model of rhinovirus induced COPD exacerbation with secondary bacterial infection also permits mechanistic and therapeutic intervention study
  • Mouse models of both permit pre-clinical studies
  • 9:50 USING A MECHANISM-DRIVEN APPROACH TO COPD DRUG DISCOVERY

    Donna Finch

    Donna Finch, Principal Scientist, Respiratory, Inflammation and Autoimmunity, MedImmune

  • COPD as a heterogeneous disease with the diagnosis covering an array of clinical phenotypes
  • Key pathological processes evident using histological methodology
  • Can mechanisms of disease be studied agnostic of clinical or genetic phenotypes?
  • Finding new targets for biotherapeutics in COPD
  • 10:30 Morning Coffee

    11:00 REPEATABILITY OF FORCED SPIROMETRY AND DIFFUSION MEASUREMENT IN A MULTICENTER CLINICAL TRIAL WITH MODERATE TO SEVERE COPD PATIENTS

    Juergen Reinstaedtler

    Juergen Reinstaedtler, Senior Product Manager, ERT

  • Is diffusion testing doable in a international multicenter study?
  • Compare the repeatability scores with the ERS/ATS 2005 guidelines
  • Show benefit of centralized quality review and rejection of poor efforts
  • Suggest tighter limits for future clinical trials and updated guidelines
  • 11:40 PROOF OF CONCEPT STUDIES IN ASTHMA AND COPD

    Nestor Molfino

    Nestor Molfino, Vice President Clinical Development, Head Respiratory Diseases, MedImmune

  • Studies in asthma and COPD subjects have historically  used pulmonary function (FEV1) as end-point
  • Current trends focus on reducing acute exacerbations and or improvements of quality of life
  • New end-points, if validated or if clinically meaningful are being considered
  • This presentation will cover such new end-points and study designs in asthma and COPD to establish Proof of Concept in drug development
  • 12:20 Networking Lunch

    13:40 THE STRATIFIED MEDICINE INNOVATION PLATFORM (SMIP)

    Zahid Latif

    Zahid Latif, Head of Healthcare, Technology Strategy Board, UK

  • Overview of Technology Strategy Board and what an Innovation Platform is
  • The objectives and scope of the Stratified Medicine Innovation Platform
  • Where asthma and COPD fit in the SMIP
  • How we invest
  • 14:20 PAN-SELECTIN ANTAGONISM AS AN ANTI-INFLAMMATORY THERAPEUTIC OPTION IN COPD AND ASTHMA

    Daniel Bock

    Daniel Bock, Director Preclinical and Clinical R&D, Revotar Biopharmaceuticals

  • Rationale for targeting selectins in pulmonary inflammation
  • Preclinical and clinical development of selectin antagonists in respiratory diseases
  • Recent clinical results of the pan-selectin antagonist Bimosiamose
  • Fitting pan-selectin antagonism into the future therapeutic armamentarium of COPD and Asthma
  • 15:00 Afternoon Tea

    15:40 ANTICHOLINERGICS BEYOND BRONCHODILATION

    Michael Paul Pieper

    Michael Paul Pieper, Senior Principal Scientist, Respiratory Diseases Research, Boehringer Ingelheim

  • Cholinergic tone in chronic airways diseases
  • Long acting anticholinergics in asthma and COPD models
  • Effects on airway inflammation and airway remodelling
  • Clinical perspective
  • 16:20 IS THERE A FUTURE FOR TRIPLE THERAPY IN COPD?

    Philippe Rogueda

    Philippe Rogueda, Adjunct Senior Lecturer, University of Monash

  • Triple therapy is becoming the standard in acute COPD
  • Yet, there are no specific triple therapy products
  • Is there a need and market for such products?
  • Review of the latest clinical and IP data to understand where the market is heading
  • 17:00 Chairman’s Closing Remarks and Close of Day Two

    +

    Workshops

    Early Clinical Studies in COPD
    Workshop

    Early Clinical Studies in COPD

    Marriott Regents Park
    12th April 2011
    London, United Kingdom

    Marriott Hotel Regents Park

    128 King Henry’s Road
    London NW3 3ST
    United Kingdom

    Marriott Hotel Regents Park

    This 4 star north London hotel in zone 2 is the perfect destination for the astute business traveler as well as the leisure guest that knows how convenient north London hotels are, as a base from which to explore the city .Bond Street is just 3 stops from Swiss Cottage underground station on the Jubilee Line, so you can be shopping, exploring the sights and taking in one of London’s world-renowned West End shows in less than 15 minutes when you stay at this hotel near central London. At the same time, the hive of activity that is Camden Town, the chic shops, cafes and restaurants of Primrose Hill and ZSL’s London Zoo in Regents Park are all just a short walk from this hotel in north London.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.